CMTX-101 / Clarametyx Biosci - LARVOL DELTA

Clarametyx Biosciences Announces Investment by Kineticos AMR Accelerator Fund (Businesswire) - "Clarametyx Biosciences Inc....and Kineticos Life Sciences...announced an investment by the Kineticos AMR Accelerator Fund I, L.P...Aligned with the investment, KAMRA Venture Partner Douglas Thomson will join the Clarametyx Board of Directors....This investment extends the Company’s Series A funding completed in 2024 to drive momentum across the Clarametyx pipeline, including the ongoing CMTX-101 trial in cystic fibrosis-related infections in collaboration with the Cystic Fibrosis Foundation, and development of the CMTX-301 vaccine against recurrent bacterial infections, which was recently funded by CARB-X."

Financing • Cystic Fibrosis

A Study to Evaluate the Safety of CMTX-101 in People with Cystic Fibrosis (clinicaltrials.gov) - P1/2 | N=41 | Recruiting | Sponsor: Clarametyx Biosciences, Inc. | Trial completion date: Feb 2025 ➔ Aug 2025 | Trial primary completion date: Feb 2025 ➔ Aug 2025

Trial completion date • Trial primary completion date • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Clarametyx Biosciences Announces Progress on Study of Antibody Therapy CMTX-101 for Infections Associated With Cystic Fibrosis (Businesswire) - "Clarametyx Biosciences....today announced that it has completed the initial Phase 1b portion of its clinical trial evaluating the novel immune-enabling antibody therapy CMTX-101 to treat cystic fibrosis (CF)-associated pulmonary infections and is now initiating the Phase 2a portion of the trial....'We are encouraged by the initial data from the 1b portion of the study, which demonstrated no safety signals with CMTX-101'....The company expects to report initial findings from the study in 2025."

P1 data • Trial status • Cystic Fibrosis

A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101 (clinicaltrials.gov) - P1 | N=28 | Terminated | Sponsor: Clarametyx Biosciences, Inc. | Data currently under review. Results will be posted when final.

Trial termination • Infectious Disease • Pneumonia • Respiratory Diseases

A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis (clinicaltrials.gov) - P1/2 | N=41 | Recruiting | Sponsor: Clarametyx Biosciences, Inc. | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101 (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Clarametyx Biosciences, Inc. | Trial completion date: Feb 2024 ➔ May 2024 | Trial primary completion date: Feb 2024 ➔ May 2024

Trial completion date • Trial primary completion date • Infectious Disease • Pneumonia • Respiratory Diseases

Clarametyx Biosciences Announces $33M Series A Financing to Advance Anti-Biofilm Biologics for Serious Bacterial Infections (BioSpace) - "Clarametyx Biosciences Inc....today announced the successful completion of a $33 million Series A round. The proceeds from the round will enable the company to accelerate efforts across its pipeline, including specifically to evaluate the potential of Clarametyx’s lead therapeutic candidate CMTX-101 to combat infection in people with cystic fibrosis (CF), a progressive, genetic disease that affects the lungs, pancreas and other organs....In coordination with the fundraising, Clarametyx has initiated a Phase 1b/2a clinical trial evaluating its lead candidate, CMTX-101, in people with CF."

Financing • Cystic Fibrosis